Telix pharmaceutical/$TLX
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Telix pharmaceutical
Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.
Ticker
$TLX
Sector
Primary listing
Employees
423
Headquarters
North Melbourne, Australia
Website
TLX Metrics
BasicAdvanced
$3.3B
231.00
$0.04
2.28
-
Price and volume
Market cap
$3.3B
Beta
2.28
52-week high
$30.36
52-week low
$8.76
Average daily volume
87K
Financial strength
Current ratio
1.333
Quick ratio
1.108
Long term debt to equity
94.134
Total debt to equity
99.126
Interest coverage (TTM)
2.64%
Profitability
EBITDA (TTM)
36.406
Gross margin (TTM)
53.94%
Net profit margin (TTM)
1.63%
Operating margin (TTM)
4.23%
Effective tax rate (TTM)
-19.94%
Revenue per employee (TTM)
$1,570,000
Management effectiveness
Return on assets (TTM)
2.08%
Return on equity (TTM)
3.14%
Valuation
Price to earnings (TTM)
231.004
Price to revenue (TTM)
3.771
Price to book
11.88
Price to tangible book (TTM)
-30.89
Price to free cash flow (TTM)
-197.383
Free cash flow yield (TTM)
-0.51%
Free cash flow per share (TTM)
-0.05
Growth
Revenue change (TTM)
55.35%
Earnings per share change (TTM)
-45.24%
3-year revenue growth (CAGR)
227.92%
3-year earnings per share growth (CAGR)
-45.54%
TLX News
AllArticlesVideos
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
Newsfile Corp9 hours ago
ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
Newsfile Corp1 day ago
ROSEN, LEADING INVESTOR COUNSEL, Encourages Telix Pharmaceuticals Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - TLX
Newsfile Corp3 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Telix pharmaceutical stock?
Telix pharmaceutical (TLX) has a market cap of $3.3B as of December 07, 2025.
What is the P/E ratio for Telix pharmaceutical stock?
The price to earnings (P/E) ratio for Telix pharmaceutical (TLX) stock is 231 as of December 07, 2025.
Does Telix pharmaceutical stock pay dividends?
No, Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders as of December 07, 2025.
When is the next Telix pharmaceutical dividend payment date?
Telix pharmaceutical (TLX) stock does not pay dividends to its shareholders.
What is the beta indicator for Telix pharmaceutical?
Telix pharmaceutical (TLX) has a beta rating of 2.28. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.